Vienna Institute for Research in Ocular Surgery
Vienna, 1040, Austria
NCT Number: NCT06948851
Epiretinal membranes (ERM) are a macular disorder leading to metamorphopsia and a decrease in visual acuity. Peeling of ERM during vitrectomy is, up to date, the only possible treatment option, opening chances for improvements of visual acuity and metamorphopsia. Occurrence of new intraretinal cystoid changes was described to be associated with a lower level of visual acuity after surgery, compared to patients, that never had intraretinal cystoid changes Aim of our study was to analyze development of new intraretinal cystoid changes after vitrectomy with membrane peeling with respect to postsurgical treatment strategies.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Vienna, 1040, Austria
Epiretinal membranes (ERM) are a macular disorder leading to metamorphopsia and a decrease in visual acuity. While ERM are rare among young people, they have prevalence rates of up to 30% in the age groups of 70 years or older. Peeling of ERM during vitrectomy is, up to date, the only possible treatment option, opening chances for improvements of visual acuity and metamorphopsia. Nevertheless, there is a risk for development of new intraretinal cystoid changes after peeling of ERM in about 10% of patients. Preoperative presence of intraretinal cystoid changes was already described as a risk factor for postsurgical presence of intraretinal cystoid changes and and occurrence of new intraretinal cystoid changes was described to be associated with a lower level of visual acuity after surgery, compared to patients, that never had intraretinal cystoid changes. Biomarker in presurgical optical coherence tomography (OCT) have been described to be associated with postsurgical results. Using a multivariable approach of analysis, presurgical DRIL and higher central macular thickness (CMT) were significant negative predictors on postsurgical visual acuity three months after surgery. However, influence of preoperative OCT biomarkers on development of new postsurgical intraretinal cystoid changes was not examined in theses studies. Aim of our study was to analyze development of new intraretinal cystoid changes after vitrectomy with membrane peeling with respect to postsurgical treatment strategies.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 months after surgery
presence of new postoperative intraretinal cystoid changes is assessed from OCT images 3 months after surgery
Time frame: 3 months after surgery
Maximum diameter is measured in µm from OCT images 3 months after surgery
Prim. Prof. Dr. Oliver Findl, MBA
Other
Development of New Postoperative Intraretinal Cystoid Changes With Respect to Postsurgical Treatment Strategies After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736690
Epiretinal Membrane, Eye Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT05145491
Epiretinal Membrane, Eye Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT02423213
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT04132401
Age-Related Macular Degeneration, Cardiovascular Diseases
Manresa, Barcelona, Spain
View Trial Details